Conference Coverage

Anastrozole provides alternative option for DCIS


 

AT THE 2015 ASCO ANNUAL MEETING

References

Dr. Don Dizon Susan London/Frontline Medical News

Dr. Don Dizon

ASCO expert Dr. Don Dizon agreed and said the results of B-35 answer a very important clinical question and will allow physicians who treat women with DCIS to counsel them on an individual level about their treatment options.

The study was funded by the National Institutes of Health. Dr. Margolese reported no relevant conflicts of interest. Dr. Dizon reported employment and a consultant or advisory board role with UpToDate and research funding to his institution from AstraZeneca and GlaxoSmithKline.

pwendling@frontlinemedcom.com

On Twitter @pwendl

Pages

Recommended Reading

Treatment of metastatic breast cancer with nab-paclitaxel in the community practice setting: a US oncology survey
MDedge Hematology and Oncology
Treatment differences between urban and rural women with hormone receptor-positive early-stage breast cancer based on 21-gene assay recurrence score result
MDedge Hematology and Oncology
A quarter of women with dense breasts at high interval cancer risk
MDedge Hematology and Oncology
ACOG spells out risk assessment for hereditary cancer syndromes
MDedge Hematology and Oncology
ASCO 2015: Dr. William J. Gradishar gives his top picks in breast cancer research
MDedge Hematology and Oncology
ASCO 2015: Dr. Hope S. Rugo gives her top picks in breast cancer research
MDedge Hematology and Oncology
VIDEO: Palbociclib may delay chemotherapy for some women with metastatic breast cancer
MDedge Hematology and Oncology
CDK inhibitor remains active as endocrine resistance emerges
MDedge Hematology and Oncology
ASCO: Enzalutamide advances in triple-negative breast cancer
MDedge Hematology and Oncology
David Henry's JCSO podcast, May 2015
MDedge Hematology and Oncology